AstraZeneca PLC (AZN.L)
LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Add to watchlist
At close: 06:03PM GMT
| Previous close | 10,250.00 |
| Open | 10,274.00 |
| Bid | 10,100.00 x 0 |
| Ask | 10,800.00 x 0 |
| Day's range | 10,274.00 - 10,578.00 |
| 52-week range | 8,214.00 - 11,886.00 |
| Volume | |
| Avg. volume | 2,076,412 |
| Market cap | 168.882B |
| Beta (5Y monthly) | 0.23 |
| PE ratio (TTM) | 101.71 |
| EPS (TTM) | 1.04 |
| Earnings date | 09 Feb 2023 |
| Forward dividend & yield | 2.22 (2.16%) |
| Ex-dividend date | 11 Aug 2022 |
| 1y target est | 122.02 |
- Zacks
Astrazeneca (AZN) Stock Sinks As Market Gains: What You Should Know
Astrazeneca (AZN) closed the most recent trading day at $63.15, moving -0.65% from the previous trading session.
- Zacks
GSK's Daprodustat Drug for Anemia Due to CKD Gets FDA Nod
GSK announces the FDA approval of daprodustat for the treatment of anemia due to chronic kidney disease (CKD) in adults on dialysis for at least four months.
- Business Wire
TEZSPIRE® approved for self-administration in the US with a new pre-filled pen
WILMINGTON, Del., February 02, 2023--AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab-ekko) has been approved in the US for self-administration in a pre-filled, single-use pen for patients aged 12 years and older with severe asthma. TEZSPIRE is the only biologic approved for severe asthma with no phenotype (e.g. eosinophilic or allergic) or biomarker limitation within its approved label.1
© 2023 Yahoo. All rights reserved.
